Search

everythinglearnresearchcommunity

for

Search:↓

A humorous discussion about hair loss treatments, specifically mentioning the use of 5mg of Dutasteride. The conversation includes jokes about the effectiveness of the treatment.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

A sugar gel containing 2-deoxy-D-ribose has shown promising hair regrowth results in mice, comparable to Minoxidil. Users are discussing the potential to buy and try this compound themselves.

The conversation is about using GHK-CU peptide for hair regrowth. Minoxidil, finasteride, and RU58841 are also mentioned as potential treatments for hair loss.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

GHK-Cu is discussed for hair loss treatment, with some users reporting positive results using a 4% topical serum, but concerns exist about the long-term safety of oral or injectable forms. The original poster also uses finasteride and plans to start dutasteride.

PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.

A 19-year-old male with no family history of androgenetic alopecia (AGA) is experiencing hair loss and considering using a topical minoxidil and finasteride mixture. Despite low vitamin D levels and normal DHT serum levels, he seeks confirmation of AGA before starting treatment.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

The conversation discusses the use of ethanol and propylene glycol (PG) in topical solutions for hair loss treatments, specifically Minoxidil. The user dislikes the texture of PG and questions the ideal ratio and necessity of PG in these solutions.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

Hair cloning claims by Dr. Gho are widely considered a scam, with skepticism about the effectiveness of his hair stem cell transplantation. Users suggest that if it were effective, wealthy individuals would opt for it over traditional methods like FUE transplants.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A 41-year-old doctor shared his positive experience with a 4,100 graft hair transplant, highlighting the importance of a skilled doctor for a natural hairline. He mentioned a confidence boost and the occasional use of finasteride post-transplant.

High prolactin levels can cause hair loss, and finasteride may increase prolactin. Cabergoline or Vitamin B6 might lower prolactin, but combining them with finasteride requires caution.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

The conversation discusses the possibility of creating liposomal topical finasteride at home or at a local pharmacy, questioning if it is an expensive or proprietary technology. It also mentions making topical finasteride using alcohol and propylene glycol.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

A user's successful hair transplant, with some people questioning the donor area regrowth, and others speculating that hair fibre may have been used to help fill in areas.

A compounding pharmacist offers affordable topical finasteride foam with Anagain and micro-dose finasteride capsules for hair loss. They provide telehealth services across Canada and private appointments for international patients.

The user is using testosterone and finasteride to prevent hair loss and is considering adding Primobolan or Masteron, which are DHT-derivatives. They are seeking advice on their genetic risk for male pattern baldness and whether they can safely use these compounds without significant hair loss.

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.